Related references
Note: Only part of the references are listed.A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET ONCOLOGY (2019)
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
Kensei Yamaguchi et al.
GASTRIC CANCER (2018)
Gastric cancer: epidemiology, prevention, classification, and treatment
Robert Sitarz et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).
Kei Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).
Daisuke Takahari et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Michael Cecchini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.
Gulam Abbas Manji et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Perspectives of HER2-targeting in gastric and esophageal cancer
James N. Gerson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
The Role of Angiogenesis in Cancer Treatment
Mehdi Rajabi et al.
BIOMEDICINES (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
H. H. Yoon et al.
ANNALS OF ONCOLOGY (2016)
FDA Approval Summary: Ramucirumab for Gastric Cancer
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Global burden of gastric cancer attributable to Helicobacter pylori
Martyn Plummer et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer
Milind Javle et al.
CLINICAL CANCER RESEARCH (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Jeffrey Melson Clarke et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Diet and the risk of gastric cancer: review of epidemiological evidence
Shoichiro Tsugane et al.
GASTRIC CANCER (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
FA Scappaticci et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity
Z Zhu et al.
LEUKEMIA (2003)
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy
D Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
JS Macdonald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
